{"id":"W4410812818","doi":"10.1200/jco.2025.43.16_suppl.tps7567","title":"Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Dexamethasone; Daratumumab; Multiple myeloma; Internal medicine; Oncology; Phases of clinical research; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007520711,0.002604591,0.002968342,0.0005813747,0.0007522298,0.001953311,0.002802001,0.002641958,0.01118487],"category_scores_gemma":[0.003430993,0.001356098,0.00236025,0.0006831954,0.001727242,0.001739575,0.001181685,0.006665587,0.002911991],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002340721,"about_ca_system_score_gemma":0.004721541,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001274877,"about_ca_topic_score_gemma":0.003605737,"domain_scores_codex":[0.9978558,0.001284964,0.00009059268,0.0002834862,0.0001806087,0.0003044767],"domain_scores_gemma":[0.9983001,0.0003147346,0.0003868039,0.0001108737,0.00009527716,0.0007922046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9152597,0.04830686,0.002935843,0.0009179453,0.0009095771,0.0001265292,0.0001435564,0.001430373,0.00496225,0.0004612968,0.0038721,0.02067401],"study_design_scores_gemma":[0.7964259,0.1946782,0.002908621,0.00006108271,0.0005111843,0.00008491623,0.00006705803,0.0007141756,0.0005967721,0.0004528576,0.003459212,0.00003991617],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.8525051,0.005308383,0.003191074,0.003892442,0.00194124,0.1141322,0.009372887,0.0003645628,0.009292088],"genre_scores_gemma":[0.8353804,0.003162327,0.0108903,0.008189355,0.001239464,0.1261352,0.006766881,0.000129058,0.008107125],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.01118487,"threshold_uncertainty_score":0.03977376,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1129897371606844,"score_gpt":0.4503265996954301,"score_spread":0.3373368625347457,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}